GLP-1 medications are some of the most heavily studied drugs of the past twenty years, and the trial names get quoted everywhere: STEP 1, SURMOUNT-4, SELECT, LEADER. This page lists every named, completed GLP-1 trial we could verify, 205 in all, with what each one tested, who sponsored it, what it found, and a link to the published paper.
It is a reference page, so it is long. Use the links below to jump to a drug or a topic.
Jump to a section
- Semaglutide for weight loss (STEP and OASIS) (16 trials)
- Tirzepatide for weight loss (SURMOUNT) (8 trials)
- Liraglutide for weight loss (SCALE) (8 trials)
- Orforglipron, the daily pill (ATTAIN and ACHIEVE) (8 trials)
- Heart, kidney and survival trials (17 trials)
- Newer uses: liver, sleep apnea, joints, brain and more (13 trials)
- Semaglutide injection for type 2 diabetes (SUSTAIN) (14 trials)
- Semaglutide pill for type 2 diabetes (PIONEER) (12 trials)
- Tirzepatide for type 2 diabetes (SURPASS) (12 trials)
- Dulaglutide (AWARD) (14 trials)
- Liraglutide for type 2 diabetes (LEAD and others) (10 trials)
- Exenatide (DURATION) (10 trials)
- Lixisenatide (GetGoal) (12 trials)
- Albiglutide (HARMONY) (4 trials)
- GLP-1 and insulin in one injection (DUAL, LixiLan, COMBINE) (24 trials)
- Drugs not yet approved in the US (23 trials)
- Who paid for these trials
- Finished trials with no published results yet (19 trials)
- How this page was built
(opens full-size image in a new tab)How to read this page
- Trial links to the trial's official record on ClinicalTrials.gov, the US government registry.
- People is the number enrolled, taken from that registry.
- Sponsor is the organization the registry lists as running and paying for the trial.
- Headline result gives the trial's main finding, using the numbers from the published paper's summary. "Points" of HbA1c means percentage points.
- Paper links to the peer-reviewed publication.
Three cautions apply to the whole page.
These are averages. A trial that reports a 15% average weight loss includes people who lost 25% and people who lost almost nothing. A trial result describes a group; it does not predict what will happen to you.
Most of these trials were paid for by the company that makes the drug. That is how nearly all drug trials are funded, and these trials were randomized, which is the strongest design available. It does not make the results wrong. It does mean the company chose what to test, what to compare against, and which results to lead with. The trials run by public bodies and charities are marked in the Sponsor column.
A placebo group is not an untreated group. In weight trials, people on placebo usually get the same diet and activity coaching as people on the drug, which is why the placebo groups often lose a few percent too.
For unfamiliar terms, see our glossary entries on GLP-1, titration, maintenance dose and weight regain.
Semaglutide for weight loss (STEP and OASIS)
STEP is Novo Nordisk's programme for weekly injected semaglutide 2.4 mg, sold as Wegovy. OASIS tests the same drug as a daily pill. Most trials compare the drug with a placebo injection or pill, with everyone also getting diet and activity advice.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| OASIS 1 (external link) | Daily semaglutide pill (50 mg) vs placebo, 68 weeks, adults with obesity and no diabetes | 667 | Novo Nordisk | Weight fell 15.1% vs 2.4% on placebo. Stomach and bowel side effects in 80% vs 46%. | Lancet, 2023 (external link) |
| OASIS 2 (external link) | Daily semaglutide pill (50 mg) vs placebo in East Asian adults, some with type 2 diabetes | 201 | Novo Nordisk | Weight fell 14.3% vs 1.3% on placebo. 4.5% stopped the pill because of side effects. | JAMA Intern Med, 2025 (external link) |
| OASIS 4 (external link) | Lower-dose daily semaglutide pill (25 mg) vs placebo, 64 weeks | 307 | Novo Nordisk | Weight fell 13.6% vs 2.2% on placebo. Stomach and bowel side effects in 74% vs 42%. | N Engl J Med, 2025 (external link) |
| STEP 1 (external link) | Weekly semaglutide 2.4 mg vs placebo, 68 weeks, adults with obesity and no diabetes | 1,961 | Novo Nordisk | Weight fell 14.9% vs 2.4% on placebo; 86% lost at least 5% of their weight vs 32%. 4.5% stopped because of stomach side effects. | N Engl J Med, 2021 (external link) |
| STEP 2 (external link) | Weekly semaglutide 2.4 mg vs 1.0 mg vs placebo, 68 weeks, adults with obesity and type 2 diabetes | 1,210 | Novo Nordisk | Weight fell 9.6% on 2.4 mg vs 3.4% on placebo, a smaller loss than in people without diabetes. | Lancet, 2021 (external link) |
| STEP 3 (external link) | Weekly semaglutide 2.4 mg vs placebo, both added to intensive behavioural therapy and a low-calorie diet, 68 weeks | 611 | Novo Nordisk | Weight fell 16.0% vs 5.7% on placebo. | JAMA, 2021 (external link) |
| STEP 4 (external link) | After 20 weeks on semaglutide, people either continued it or were switched to placebo for 48 weeks | 902 | Novo Nordisk | Those who continued lost a further 7.9%; those switched to placebo regained 6.9%. | JAMA, 2021 (external link) |
| STEP 5 (external link) | Weekly semaglutide 2.4 mg vs placebo for two years (104 weeks) | 304 | Novo Nordisk | Weight was 15.2% lower at two years vs 2.6% on placebo, showing the loss held. | Nat Med, 2022 (external link) |
| STEP 6 (external link) | Weekly semaglutide 2.4 mg or 1.7 mg vs placebo, 68 weeks, adults in Japan and South Korea | 401 | Novo Nordisk | Weight fell 13.2% (2.4 mg) and 9.6% (1.7 mg) vs 2.1%. Deep belly fat fell 40% on the higher dose. | Lancet Diabetes Endocrinol, 2022 (external link) |
| STEP 7 (external link) | Weekly semaglutide 2.4 mg vs placebo, 44 weeks, mostly East Asian adults, with or without type 2 diabetes | 375 | Novo Nordisk | Weight fell 12.1% vs 3.6% on placebo. | Lancet Diabetes Endocrinol, 2024 (external link) |
| STEP 8 (external link) | Weekly semaglutide 2.4 mg vs daily liraglutide 3.0 mg, 68 weeks, head to head | 338 | Novo Nordisk | Weight fell 15.8% on semaglutide vs 6.4% on liraglutide. 13.5% vs 27.6% stopped treatment. | JAMA, 2022 (external link) |
| STEP 10 (external link) | Weekly semaglutide 2.4 mg vs placebo, 52 weeks, adults with obesity and prediabetes | 207 | Novo Nordisk | Weight fell 13.9% vs 2.7%. Blood sugar returned to the normal range in 81% vs 14%. | Lancet Diabetes Endocrinol, 2024 (external link) |
| STEP 11 (external link) | Weekly semaglutide 2.4 mg vs placebo, 44 weeks, adults in South Korea and Thailand with BMI 25 or above | 150 | Novo Nordisk | Weight fell 16.0% vs 3.1% on placebo. | Lancet Diabetes Endocrinol, 2025 (external link) |
| STEP 12 (external link) | Weekly semaglutide 2.4 mg vs placebo in Chinese adults with overweight or obesity | 242 | Novo Nordisk | Weight fell 12.1% vs 2.2% on placebo. | Lancet Diabetes Endocrinol, 2026 (external link) |
| STEP TEENS (external link) | Weekly semaglutide 2.4 mg vs placebo, 68 weeks, adolescents aged 12 to 17 with obesity | 201 | Novo Nordisk | BMI fell 16.1% vs a 0.6% rise on placebo. Gallstones occurred in 4% on semaglutide and none on placebo. | N Engl J Med, 2022 (external link) |
| STEP UP (external link) | A higher weekly semaglutide dose (7.2 mg) vs 2.4 mg vs placebo, 72 weeks | 1,407 | Novo Nordisk | Weight fell 18.7% on 7.2 mg, 15.6% on 2.4 mg and 3.9% on placebo. Tingling or altered skin sensation in 23% on the high dose vs 6% on 2.4 mg. | Lancet Diabetes Endocrinol, 2025 (external link) |
Tirzepatide for weight loss (SURMOUNT)
SURMOUNT is Eli Lilly's programme for weekly tirzepatide, sold as Zepbound. Tirzepatide acts on two gut-hormone pathways, GIP and GLP-1. Two of these trials ask what happens afterwards: SURMOUNT-4 tests stopping, and SURMOUNT-MAINTAIN tests stepping down to a lower dose.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| SURMOUNT-1 (external link) | Weekly tirzepatide 5, 10 or 15 mg vs placebo, 72 weeks, adults with obesity and no diabetes | 2,539 | Eli Lilly | Weight fell 15.0%, 19.5% and 20.9% across the three doses vs 3.1% on placebo. More than half on the top dose lost at least 20%. | N Engl J Med, 2022 (external link) |
| SURMOUNT-2 (external link) | Weekly tirzepatide 10 or 15 mg vs placebo, 72 weeks, adults with obesity and type 2 diabetes | 938 | Eli Lilly | Weight fell 12.8% and 14.7% vs 3.2% on placebo, a smaller loss than in people without diabetes. | Lancet, 2023 (external link) |
| SURMOUNT-3 (external link) | Tirzepatide vs placebo for 72 weeks, in people who had already lost at least 5% through an intensive lifestyle programme | 579 | Eli Lilly | A further 18.4% loss on tirzepatide vs a 2.5% regain on placebo. | Nat Med, 2023 (external link) |
| SURMOUNT-4 (external link) | After 36 weeks on tirzepatide, people either continued it or were switched to placebo for 52 weeks | 783 | Eli Lilly | Those who continued lost a further 5.5%; those switched to placebo regained 14.0%. 89.5% vs 16.6% kept at least four-fifths of their loss. | JAMA, 2024 (external link) |
| SURMOUNT-5 (external link) | Tirzepatide vs semaglutide head to head, each at the highest tolerated dose, 72 weeks, open-label | 751 | Eli Lilly | Weight fell 20.2% on tirzepatide vs 13.7% on semaglutide. | N Engl J Med, 2025 (external link) |
| SURMOUNT-CN (external link) | Weekly tirzepatide 10 or 15 mg vs placebo, 52 weeks, Chinese adults | 210 | Eli Lilly | Weight fell 13.6% and 17.5% vs 2.3% on placebo. | JAMA, 2024 (external link) |
| SURMOUNT-J (external link) | Weekly tirzepatide 10 or 15 mg vs placebo, 72 weeks, Japanese adults with obesity disease | 267 | Eli Lilly | Weight fell 16.1 and 21.1 percentage points more than placebo on the two doses. | Lancet Diabetes Endocrinol, 2025 (external link) |
| SURMOUNT-MAINTAIN (external link) | After 60 weeks at full dose, people continued it, stepped down to 5 mg, or switched to placebo for a year | 441 | Eli Lilly | At week 112 weight was 21.9% (full dose), 16.6% (5 mg) and 9.9% (placebo) below the start. 8%, 25% and 67% regained at least half their loss. | Lancet, 2026 (external link) |
Liraglutide for weight loss (SCALE)
SCALE tested daily liraglutide 3.0 mg, sold as Saxenda, the first GLP-1 approved for weight management. The weight losses are smaller than with the newer weekly drugs above, which is visible in the numbers.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| SCALE Diabetes (external link) | Daily liraglutide 3.0 mg or 1.8 mg vs placebo, 56 weeks, adults with overweight and type 2 diabetes | 846 | Novo Nordisk | 54% on 3.0 mg lost at least 5% of their weight vs 21% on placebo; 25% vs 7% lost more than 10%. | JAMA, 2015 (external link) |
| SCALE IBT (external link) | Daily liraglutide 3.0 mg vs placebo, both added to intensive behavioural therapy in primary care, 56 weeks | 282 | Novo Nordisk | Weight fell 7.5% vs 4.0% on placebo. | Obesity (Silver Spring), 2020 (external link) |
| SCALE Insulin (external link) | Daily liraglutide 3.0 mg vs placebo plus behavioural therapy, adults with type 2 diabetes on insulin, 56 weeks | 396 | Novo Nordisk | Weight fell 5.8% vs 1.5% on placebo, with lower insulin doses and no rise in low blood sugar. | Diabetes Care, 2020 (external link) |
| SCALE Kids (external link) (registry: follow-up still running) | Daily liraglutide vs placebo, 56 weeks, children aged 6 to under 12 with obesity | 78 | Novo Nordisk | BMI fell 5.8% vs a 1.6% rise on placebo. 46% vs 9% cut their BMI by at least 5%. | N Engl J Med, 2025 (external link) |
| SCALE Maintenance (external link) | After losing at least 5% on a low-calorie diet, people took daily liraglutide 3.0 mg or placebo for 56 weeks | 422 | Novo Nordisk | A further 6.2% loss on liraglutide vs 0.2% on placebo. 81% vs 49% kept their diet-phase loss. | Int J Obes (Lond), 2013 (external link) |
| SCALE Obesity and Prediabetes (external link) | Daily liraglutide 3.0 mg vs placebo, 56 weeks, adults with obesity and no diabetes | 3,731 | Novo Nordisk | Weight fell 8.4 kg vs 2.8 kg on placebo; 63% vs 27% lost at least 5% of their weight. | N Engl J Med, 2015 (external link) |
| SCALE Sleep Apnea (external link) | Daily liraglutide 3.0 mg vs placebo, 32 weeks, adults with obesity and moderate or severe sleep apnea | 359 | Novo Nordisk | Breathing interruptions fell by 12.2 vs 6.1 an hour. Weight fell 5.7% vs 1.6%. | Int J Obes (Lond), 2016 (external link) |
| SCALE Teens (external link) | Daily liraglutide 3.0 mg vs placebo plus lifestyle therapy, 56 weeks, adolescents aged 12 to 17 | 251 | Novo Nordisk | BMI fell about 4.6 percentage points more than placebo. 10.4% stopped liraglutide because of side effects vs none on placebo, and BMI rose faster after stopping. | N Engl J Med, 2020 (external link) |
Orforglipron, the daily pill (ATTAIN and ACHIEVE)
Orforglipron is a GLP-1 pill that is not a peptide, so it needs no food or water restrictions. ATTAIN covers weight loss and ACHIEVE covers type 2 diabetes. ATTAIN-MAINTAIN is the first trial of switching from an injection to a pill; our guide on switching from a GLP-1 injection to a pill covers it in depth.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| ACHIEVE-1 (external link) | Daily orforglipron pill (3, 12 or 36 mg) vs placebo, 40 weeks, early type 2 diabetes managed by diet and exercise | 559 | Eli Lilly | HbA1c fell 0.83 to 1.07 percentage points more than placebo, from 8.0% to about 6.5 to 6.7%. | N Engl J Med, 2025 (external link) |
| ACHIEVE-2 (external link) | Daily orforglipron pill vs dapagliflozin, 40 weeks, type 2 diabetes on metformin | 962 | Eli Lilly | HbA1c fell 1.23 to 1.56 points on orforglipron vs 0.81 on dapagliflozin. | Lancet, 2026 (external link) |
| ACHIEVE-3 (external link) | Daily orforglipron pill vs the semaglutide pill, 52 weeks, open-label, type 2 diabetes on metformin | 1,698 | Eli Lilly | HbA1c fell 1.71 and 1.91 points on orforglipron 12 and 36 mg vs 1.23 and 1.47 on semaglutide 7 and 14 mg. | Lancet, 2026 (external link) |
| ACHIEVE-5 (external link) | Daily orforglipron pill vs placebo added to insulin glargine, 40 weeks, type 2 diabetes | 546 | Eli Lilly | HbA1c fell 1.58 to 1.88 points vs 0.79 on placebo. | JAMA, 2026 (external link) |
| ACHIEVE-J (external link) | One-year safety study of three orforglipron doses in Japanese adults with type 2 diabetes (no placebo group) | 401 | Eli Lilly | 85% reported a side effect. 5%, 8% and 14% stopped treatment because of side effects on 3, 12 and 36 mg. | Lancet Diabetes Endocrinol, 2026 (external link) |
| ATTAIN-1 (external link) (registry: follow-up still running) | Daily orforglipron pill (6, 12 or 36 mg) vs placebo, 72 weeks, adults with obesity and no diabetes | 3,127 | Eli Lilly | Weight fell 7.5%, 8.4% and 11.2% vs 2.1% on placebo. 5.3 to 10.3% stopped because of side effects vs 2.7%. | N Engl J Med, 2025 (external link) |
| ATTAIN-2 (external link) | Daily orforglipron pill vs placebo, 72 weeks, adults with obesity and type 2 diabetes | 1,613 | Eli Lilly | Weight fell 5.1%, 7.0% and 9.6% across the three doses vs 2.5% on placebo. | Lancet, 2026 (external link) |
| ATTAIN-MAINTAIN (external link) | After 72 weeks on injectable tirzepatide or semaglutide, people switched to the orforglipron pill or placebo for a year | 376 | Eli Lilly | Pill-takers kept 75% (after tirzepatide) and 79% (after semaglutide) of their loss vs 49% and 38% on placebo. No group stayed on the injection. | Nat Med, 2026 (external link) |
Heart, kidney and survival trials
These are the largest trials on this page. Instead of measuring blood sugar or weight, they count events: heart attacks, strokes, deaths, kidney failure, hospital stays for heart failure. Regulators required many of them to prove the drugs were safe for the heart; several went further and showed a benefit. A hazard ratio below 1 means fewer events on the drug, so 0.80 means a 20% lower rate.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| ELIXA (external link) | Daily lixisenatide vs placebo in 6,068 people with type 2 diabetes and a recent heart attack or unstable angina | 6,068 | Sanofi | No difference in heart events: 13.4% vs 13.2% (hazard ratio 1.02). Safe for the heart, but no benefit. | N Engl J Med, 2015 (external link) |
| EXSCEL (external link) | Weekly exenatide vs placebo in 14,752 people with type 2 diabetes, with or without heart disease | 14,752 | AstraZeneca | Major heart events in 11.4% vs 12.2% (hazard ratio 0.91). Safe, but narrowly missed showing a benefit. | N Engl J Med, 2017 (external link) |
| FIGHT (external link) | Daily liraglutide vs placebo for 180 days in 300 people recently hospitalised with advanced heart failure and a weak heart pump | 300 | Duke University (not a drug company); with National Heart, Lung, and Blood Institute (NHLBI) | No benefit. Deaths 12% vs 11%; heart-failure readmissions 41% vs 34%, a difference that could be chance. | JAMA, 2016 (external link) |
| FLOW (external link) | Weekly semaglutide 1.0 mg vs placebo in 3,533 people with type 2 diabetes and chronic kidney disease | 3,533 | Novo Nordisk | Major kidney events were 24% less likely (hazard ratio 0.76). | N Engl J Med, 2024 (external link) |
| FREEDOM-CVO (external link) | An implanted pump delivering exenatide continuously (ITCA 650) vs placebo in 4,156 people with type 2 diabetes | 4,156 | Intarcia | Heart events in 4.6% vs 3.8% (hazard ratio 1.21). Met the safety threshold; the authors called for a larger, longer trial. | Nat Med, 2022 (external link) |
| Harmony Outcomes (external link) | Weekly albiglutide vs placebo in 9,463 people with type 2 diabetes and heart disease, median 1.6 years | 9,463 | GSK | Major heart events in 7% vs 9% (hazard ratio 0.78). | Lancet, 2018 (external link) |
| LEADER (external link) | Daily liraglutide vs placebo in 9,341 people with type 2 diabetes at high heart risk | 9,341 | Novo Nordisk | Major heart events in 13.0% vs 14.9% (hazard ratio 0.87). Deaths from heart causes 4.7% vs 6.0%. | N Engl J Med, 2016 (external link) |
| PIONEER 6 (external link) | Daily semaglutide pill vs placebo in 3,183 people with type 2 diabetes at high heart risk | 3,183 | Novo Nordisk | Major heart events in 3.8% vs 4.8% (hazard ratio 0.79). Shown to be safe; too small to prove a benefit. | N Engl J Med, 2019 (external link) |
| REWIND (external link) | Weekly dulaglutide vs placebo in 9,901 people with type 2 diabetes, most without prior heart disease, median 5.4 years | 9,901 | Eli Lilly | Major heart events in 12.0% vs 13.4% (hazard ratio 0.88). No difference in deaths from any cause. | Lancet, 2019 (external link) |
| SELECT (external link) | Weekly semaglutide 2.4 mg vs placebo in 17,604 people with heart disease and overweight or obesity, but no diabetes | 17,604 | Novo Nordisk | Heart attack, stroke or heart death in 6.5% vs 8.0% (hazard ratio 0.80). 16.6% vs 8.2% stopped because of side effects. | N Engl J Med, 2023 (external link) |
| SOUL (external link) | Daily semaglutide pill vs placebo in 9,651 people with type 2 diabetes plus heart or kidney disease | 9,651 | Novo Nordisk | Major heart events in 12.0% vs 13.8% (hazard ratio 0.86). | N Engl J Med, 2025 (external link) |
| STEP-HFpEF (external link) | Weekly semaglutide 2.4 mg vs placebo, 52 weeks, heart failure with preserved pumping and obesity | 529 | Novo Nordisk | Symptom score improved 16.6 vs 8.7 points, six-minute walk improved 21.5 m vs 1.2 m, weight fell 13.3% vs 2.6%. | N Engl J Med, 2023 (external link) |
| STEP-HFpEF DM (external link) | Weekly semaglutide 2.4 mg vs placebo, 52 weeks, heart failure with preserved pumping, obesity and type 2 diabetes | 617 | Novo Nordisk | Symptom score improved 13.7 vs 6.4 points. Weight fell 9.8% vs 3.4%. | N Engl J Med, 2024 (external link) |
| STRIDE (external link) | Weekly semaglutide 1.0 mg vs placebo, 52 weeks, 792 people with type 2 diabetes and leg-artery disease that limits walking | 792 | Novo Nordisk | Maximum walking distance improved about 13% more than placebo. | Lancet, 2025 (external link) |
| SUMMIT (external link) | Weekly tirzepatide vs placebo, median two years, 731 people with heart failure with preserved pumping and obesity | 731 | Eli Lilly | Heart death or worsening heart failure in 9.9% vs 15.3% (hazard ratio 0.62), driven by fewer heart-failure events. Heart deaths were 8 vs 5. | N Engl J Med, 2025 (external link) |
| SURPASS-CVOT (external link) | Tirzepatide vs dulaglutide head to head in 13,299 people with type 2 diabetes and heart disease | 13,299 | Eli Lilly | Major heart events in 12.2% vs 13.1% (hazard ratio 0.92). As good as dulaglutide; did not prove better. | N Engl J Med, 2025 (external link) |
| SUSTAIN 6 (external link) | Weekly semaglutide vs placebo for two years in 3,297 people with type 2 diabetes at high heart risk | 3,297 | Novo Nordisk | Major heart events in 6.6% vs 8.9% (hazard ratio 0.74). Eye complications from diabetes were more common (hazard ratio 1.76). | N Engl J Med, 2016 (external link) |
Newer uses: liver, sleep apnea, joints, brain and more
Trials testing GLP-1 drugs for conditions beyond weight and blood sugar. This section includes some clear failures, which matter as much as the successes: two large trials found no benefit in early Alzheimer's disease, and a smaller one found none in Parkinson's disease.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| ADJUNCT ONE (external link) | Daily liraglutide vs placebo added to insulin, 52 weeks, 1,398 adults with type 1 diabetes | 1,398 | Novo Nordisk | HbA1c fell 0.20 points more than placebo on the top dose, and weight fell 4.9 kg more. Low blood sugar was more frequent, and high blood sugar with ketones doubled on the top dose. | Diabetes Care, 2016 (external link) |
| ADJUNCT TWO (external link) | Daily liraglutide vs placebo added to capped insulin, 26 weeks, 835 adults with type 1 diabetes | 835 | Novo Nordisk | HbA1c fell 0.33 points on the top dose vs no change on placebo; weight fell 5.1 kg vs 0.2 kg. More ketone episodes on the top dose. | Diabetes Care, 2016 (external link) |
| ESSENCE (external link) (registry: follow-up still running) | Weekly semaglutide 2.4 mg vs placebo in people with fatty liver disease with inflammation and scarring (MASH); 72-week results of an ongoing trial | 1,205 | Novo Nordisk | Liver inflammation resolved without worse scarring in 62.9% vs 34.3%. Weight fell 10.5% vs 2.0%. The trial continues to 240 weeks. | N Engl J Med, 2025 (external link) |
| EVOKE (external link) (people: randomized count from the paper) | Daily semaglutide pill vs placebo for two years in 1,855 people with early Alzheimer's disease | 1,855 | Novo Nordisk | No benefit. Dementia scores worsened by the same amount in both groups (2.3 vs 2.3 points). | Lancet, 2026 (external link) |
| EVOKE Plus (external link) (people: randomized count from the paper) | A parallel trial with the same design as EVOKE (daily semaglutide pill vs placebo in early Alzheimer's disease) that also admitted people with significant small vessel disease in the brain | 1,953 | Novo Nordisk | No benefit. Dementia scores worsened by 2.2 points on semaglutide vs 2.1 on placebo. | Lancet, 2026 (external link) |
| Exenatide-PD3 (external link) | Weekly exenatide vs placebo for 96 weeks in 194 people with Parkinson's disease | 194 | University College, London (not a drug company) | No benefit. Movement scores worsened by 5.7 points on exenatide vs 4.5 on placebo. Publicly and charity funded. | Lancet, 2025 (external link) |
| LEAN (external link) | Daily liraglutide vs placebo, 48 weeks, 52 people with fatty liver disease with inflammation (phase 2) | 52 | University of Birmingham (not a drug company); with Wellcome Trust, Novo Nordisk | Liver inflammation resolved in 9 of 23 (39%) vs 2 of 22 (9%). Small, early trial; funded by charities, the UK health research institute and Novo Nordisk. | Lancet, 2016 (external link) |
| RISE Adult (external link) | Liraglutide plus metformin, metformin alone, insulin then metformin, or placebo for a year in adults with prediabetes or new type 2 diabetes | 267 | RISE Study Group (not a drug company); with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Insulin-producing cell function improved during treatment, but the gain was gone three months after stopping. Publicly funded. | Diabetes Care, 2019 (external link) |
| STEP 9 (external link) | Weekly semaglutide 2.4 mg vs placebo, 68 weeks, 407 people with obesity and painful knee osteoarthritis | 407 | Novo Nordisk | Knee pain score fell 41.7 vs 27.5 points (on a 100-point scale). Weight fell 13.7% vs 3.2%. | N Engl J Med, 2024 (external link) |
| SURMOUNT-OSA (external link) | Weekly tirzepatide vs placebo, 52 weeks, 469 people with obesity and moderate or severe sleep apnea, in two parallel trials | 469 | Eli Lilly | Breathing interruptions fell by 25 to 29 an hour vs about 5 on placebo. | N Engl J Med, 2024 (external link) |
| SYNERGY-NASH (external link) | Weekly tirzepatide (5, 10 or 15 mg) vs placebo, 52 weeks, 190 people with MASH and liver scarring (phase 2) | 190 | Eli Lilly | Liver inflammation resolved without worse scarring in 44%, 56% and 62% vs 10% on placebo. The authors say larger, longer trials are needed. | N Engl J Med, 2024 (external link) |
| TOGETHER-PsA (external link) | Ixekizumab with or without tirzepatide, 36 weeks, 279 adults with psoriatic arthritis and overweight or obesity | 279 | Eli Lilly | 31.7% reached both a 50% joint improvement and a 10% weight loss vs 0.8% on ixekizumab alone. | Arthritis Rheumatol, 2026 (external link) |
| TOGETHER-PsO (external link) | Ixekizumab with or without tirzepatide, 36 weeks, 281 adults with psoriasis and overweight or obesity | 281 | Eli Lilly | 27.1% reached both completely clear skin and a 10% weight loss vs 5.8%. Clear skin alone: 40.6% vs 29.0%. | JAMA Dermatol, 2026 (external link) |
Semaglutide injection for type 2 diabetes (SUSTAIN)
SUSTAIN tested weekly injected semaglutide, sold as Ozempic, mostly against other diabetes drugs. The main measure is HbA1c, a blood test reflecting average blood sugar over about three months. A fall of 1 point, for example from 8% to 7%, is a substantial improvement.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| SUSTAIN 1 (external link) | Weekly semaglutide 0.5 or 1.0 mg vs placebo, 30 weeks, adults managing type 2 diabetes with diet and exercise only | 388 | Novo Nordisk | HbA1c fell 1.45 and 1.55 points vs 0.02 on placebo. | Lancet Diabetes Endocrinol, 2017 (external link) |
| SUSTAIN 2 (external link) | Weekly semaglutide 0.5 or 1.0 mg vs sitagliptin, 56 weeks, adults on metformin or a glitazone | 1,231 | Novo Nordisk | HbA1c fell 1.3 and 1.6 points vs 0.5. Weight fell 4.3 and 6.1 kg vs 1.9 kg. | Lancet Diabetes Endocrinol, 2017 (external link) |
| SUSTAIN 3 (external link) | Weekly semaglutide 1.0 mg vs weekly exenatide, 56 weeks, open-label | 813 | Novo Nordisk | HbA1c fell 1.5 vs 0.9 points; weight fell 5.6 vs 1.9 kg. | Diabetes Care, 2018 (external link) |
| SUSTAIN 4 (external link) | Weekly semaglutide vs daily insulin glargine, 30 weeks, open-label, adults new to insulin | 1,089 | Novo Nordisk | Weight fell 3.5 and 5.2 kg on semaglutide vs a 1.2 kg gain on insulin. Significant low blood sugar in 4 to 6% vs 11%. | Lancet Diabetes Endocrinol, 2017 (external link) |
| SUSTAIN 5 (external link) | Weekly semaglutide vs placebo added to basal insulin, 30 weeks | 397 | Novo Nordisk | HbA1c fell 1.4 and 1.8 points vs 0.1 on placebo. Weight fell 3.7 and 6.4 kg vs 1.4 kg. | J Clin Endocrinol Metab, 2018 (external link) |
| SUSTAIN 7 (external link) | Weekly semaglutide vs weekly dulaglutide, low dose vs low and high vs high, 40 weeks, open-label | 1,201 | Novo Nordisk | HbA1c fell 1.8 vs 1.4 points at the high doses. Weight fell 6.5 vs 3.0 kg. | Lancet Diabetes Endocrinol, 2018 (external link) |
| SUSTAIN 8 (external link) | Weekly semaglutide 1.0 mg vs daily canagliflozin, 52 weeks, adults on metformin | 788 | Novo Nordisk | HbA1c fell 0.49 points more and weight 1.06 kg more on semaglutide. 10% vs 5% stopped because of side effects. | Lancet Diabetes Endocrinol, 2019 (external link) |
| SUSTAIN 9 (external link) | Weekly semaglutide 1.0 mg vs placebo added to an SGLT-2 inhibitor, 30 weeks | 302 | Novo Nordisk | HbA1c fell 1.42 points more than placebo and weight 3.81 kg more. | Lancet Diabetes Endocrinol, 2019 (external link) |
| SUSTAIN 10 (external link) | Weekly semaglutide 1.0 mg vs daily liraglutide 1.2 mg, 30 weeks, open-label | 577 | Novo Nordisk | HbA1c fell 1.7 vs 1.0 points; weight fell 5.8 vs 1.9 kg. 11.4% vs 6.6% stopped because of side effects. | Diabetes Metab, 2020 (external link) |
| SUSTAIN 11 (external link) | Weekly semaglutide vs mealtime insulin three times a day, both added to basal insulin, 52 weeks | 2,274 | Novo Nordisk | HbA1c fell 1.5 vs 1.2 points. Weight fell 4.1 kg on semaglutide vs a 2.8 kg gain on mealtime insulin. | Diabetes Obes Metab, 2022 (external link) |
| SUSTAIN China (external link) | Weekly semaglutide 0.5 or 1.0 mg vs sitagliptin, 30 weeks, 868 mostly Chinese adults on metformin (SUSTAIN China) | 868 | Novo Nordisk | Both semaglutide doses lowered HbA1c and weight more than sitagliptin. The abstract gives no figures. | Diabetes Obes Metab, 2021 (external link) |
| SUSTAIN FORTE (external link) | Weekly semaglutide 2.0 mg vs 1.0 mg, 40 weeks, adults with poorly controlled type 2 diabetes | 961 | Novo Nordisk | HbA1c fell 2.2 vs 1.9 points; weight fell 6.9 vs 6.0 kg. A modest gain from doubling the dose. | Lancet Diabetes Endocrinol, 2021 (external link) |
| SUSTAIN Japan (vs oral drugs) (external link) | Weekly semaglutide vs one added oral diabetes drug, 56 weeks, open-label, 601 Japanese adults | 601 | Novo Nordisk | HbA1c fell 1.7 and 2.0 points vs 0.7. Weight fell 1.4 and 3.2 kg vs a 0.4 kg gain. | Diabetes Obes Metab, 2018 (external link) |
| SUSTAIN Japan (vs sitagliptin) (external link) | Weekly semaglutide vs sitagliptin as the only diabetes drug, 30 weeks, 308 Japanese adults | 308 | Novo Nordisk | HbA1c fell 1.9 and 2.2 points vs 0.7. 14.7% stopped the higher semaglutide dose early vs 2.9% on sitagliptin. | Diabetes Obes Metab, 2018 (external link) |
Semaglutide pill for type 2 diabetes (PIONEER)
PIONEER tested semaglutide as a daily pill, sold as Rybelsus, the first GLP-1 that did not need an injection.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| PIONEER 1 (external link) | Daily semaglutide pill (3, 7 or 14 mg) vs placebo, 26 weeks, adults managing type 2 diabetes with diet and exercise | 703 | Novo Nordisk | HbA1c fell 0.6, 0.9 and 1.1 points more than placebo. Weight fell 2.3 kg more on the top dose only. | Diabetes Care, 2019 (external link) |
| PIONEER 2 (external link) | Daily semaglutide pill 14 mg vs empagliflozin, 52 weeks, open-label, adults on metformin | 822 | Novo Nordisk | HbA1c fell 1.3 vs 0.9 points at 26 weeks. Weight loss was similar at 26 weeks and modestly better on the pill at 52. | Diabetes Care, 2019 (external link) |
| PIONEER 3 (external link) | Daily semaglutide pill (3, 7 or 14 mg) vs sitagliptin, 78 weeks, 1,864 adults on metformin | 1,864 | Novo Nordisk | HbA1c fell 0.3 and 0.5 points more than sitagliptin on the 7 and 14 mg doses; the 3 mg dose was not better. 19.1% stopped the top dose early vs 13.1%. | JAMA, 2019 (external link) |
| PIONEER 4 (external link) | Daily semaglutide pill vs injected liraglutide vs placebo, 52 weeks, adults on metformin | 711 | Novo Nordisk | The pill lowered HbA1c as well as liraglutide and better than placebo, and lowered weight more than both. The abstract gives no figures here. | Lancet, 2019 (external link) |
| PIONEER 5 (external link) | Daily semaglutide pill vs placebo, 26 weeks, 324 adults with type 2 diabetes and moderately reduced kidney function (average age 70) | 324 | Novo Nordisk | HbA1c fell 1.0 vs 0.2 points; weight fell 3.4 vs 0.9 kg. | Lancet Diabetes Endocrinol, 2019 (external link) |
| PIONEER 7 (external link) | Daily semaglutide pill with the dose adjusted to response vs sitagliptin, 52 weeks | 504 | Novo Nordisk | 58% vs 25% reached an HbA1c below 7%. | Lancet Diabetes Endocrinol, 2019 (external link) |
| PIONEER 8 (external link) | Daily semaglutide pill vs placebo added to insulin, 52 weeks, 731 adults | 731 | Novo Nordisk | At 26 weeks HbA1c fell 0.5, 0.9 and 1.2 points more than placebo, and weight up to 3.3 kg more. | Diabetes Care, 2019 (external link) |
| PIONEER 9 (external link) | Daily semaglutide pill vs placebo vs open-label liraglutide 0.9 mg, 243 Japanese adults | 243 | Novo Nordisk | HbA1c fell 1.1, 1.5 and 1.7 points on the pill vs 0.1 on placebo and 1.4 on liraglutide. | Lancet Diabetes Endocrinol, 2020 (external link) |
| PIONEER 10 (external link) | Daily semaglutide pill vs weekly dulaglutide 0.75 mg, 52 weeks, 458 Japanese adults, open-label | 458 | Novo Nordisk | HbA1c fell 0.9, 1.4 and 1.7 points on the three pill doses vs 1.4 on dulaglutide. | Lancet Diabetes Endocrinol, 2020 (external link) |
| PIONEER 11 (external link) | Daily semaglutide pill vs placebo, 26 weeks, 521 mostly Chinese adults on no diabetes drugs | 521 | Novo Nordisk | HbA1c fell 1.0, 1.4 and 1.5 points more than placebo. Weight fell on the two higher doses only. | Diabetologia, 2024 (external link) |
| PIONEER 12 (external link) | Daily semaglutide pill vs sitagliptin, 26 weeks, 1,441 mostly Chinese adults on metformin | 1,441 | Novo Nordisk | HbA1c fell 0.2, 0.7 and 1.0 points more than sitagliptin. 15.0% stopped the top dose early vs 4.2% on sitagliptin. | Diabetologia, 2024 (external link) |
| PIONEER PLUS (external link) | Higher doses of the semaglutide pill (25 and 50 mg) vs the standard 14 mg, 52 weeks, 1,606 adults | 1,606 | Novo Nordisk | HbA1c fell 1.5, 1.8 and 2.0 points on 14, 25 and 50 mg. | Lancet, 2023 (external link) |
Tirzepatide for type 2 diabetes (SURPASS)
SURPASS is the diabetes programme for weekly tirzepatide, sold as Mounjaro. SURPASS-2 is the head-to-head comparison with semaglutide 1 mg.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| SURPASS J-combo (external link) | One-year safety study of tirzepatide 5, 10 or 15 mg added to one oral diabetes drug, 443 Japanese adults (no comparison group) | 443 | Eli Lilly | HbA1c fell from about 8.5% to 5.6 to 6.0%. Weight fell 5.1%, 10.1% and 13.2%. | Lancet Diabetes Endocrinol, 2022 (external link) |
| SURPASS J-mono (external link) | Weekly tirzepatide vs weekly dulaglutide 0.75 mg, 52 weeks, 636 Japanese adults | 636 | Eli Lilly | Weight fell 7.8%, 11.0% and 13.9% on tirzepatide vs 0.7% on dulaglutide. | Lancet Diabetes Endocrinol, 2022 (external link) |
| SURPASS-1 (external link) | Weekly tirzepatide (5, 10 or 15 mg) vs placebo, 40 weeks, adults managing type 2 diabetes with diet and exercise | 478 | Eli Lilly | HbA1c fell 1.87, 1.89 and 2.07 points vs a 0.04 rise on placebo. | Lancet, 2021 (external link) |
| SURPASS-2 (external link) | Weekly tirzepatide vs weekly semaglutide 1 mg, 40 weeks, open-label, 1,879 adults on metformin | 1,879 | Eli Lilly | HbA1c fell 2.01, 2.24 and 2.30 points on tirzepatide vs 1.86 on semaglutide. Weight fell 1.9, 3.6 and 5.5 kg more. | N Engl J Med, 2021 (external link) |
| SURPASS-3 (external link) | Weekly tirzepatide vs daily insulin degludec, 52 weeks, open-label, 1,444 adults | 1,444 | Eli Lilly | HbA1c fell 1.93 to 2.37 points vs 1.34 on insulin. Weight fell 7.5 to 12.9 kg vs a 2.3 kg gain. Significant low blood sugar in 1 to 2% vs 7%. | Lancet, 2021 (external link) |
| SURPASS-4 (external link) | Weekly tirzepatide vs daily insulin glargine, 52 weeks, 2,002 adults with type 2 diabetes and high heart risk | 2,002 | Eli Lilly | HbA1c fell 2.43 and 2.58 points on 10 and 15 mg vs 1.44 on insulin. | Lancet, 2021 (external link) |
| SURPASS-5 (external link) | Weekly tirzepatide vs placebo added to insulin glargine, 40 weeks, 475 adults | 475 | Eli Lilly | HbA1c fell 2.11 to 2.40 points vs 0.86 on placebo. 10 to 18% stopped tirzepatide early vs 3%. | JAMA, 2022 (external link) |
| SURPASS-6 (external link) | Weekly tirzepatide vs mealtime insulin three times a day, both added to basal insulin, 52 weeks, 1,428 adults | 1,428 | Eli Lilly | HbA1c fell 2.1 vs 1.1 points, reaching 6.7% vs 7.7%. | JAMA, 2023 (external link) |
| SURPASS-AP-Combo (external link) | Weekly tirzepatide vs daily insulin glargine, 40 weeks, open-label, 917 adults in China, South Korea, Australia and India | 917 | Eli Lilly | HbA1c fell 2.24 to 2.49 points vs 0.95 on insulin. | Nat Med, 2023 (external link) |
| SURPASS-CN-INS (external link) | Weekly tirzepatide vs placebo added to insulin glargine, 40 weeks, 257 adults in China | 257 | Eli Lilly | HbA1c fell 2.39 and 2.37 points on 10 and 15 mg vs 0.91 on placebo. | Lancet Diabetes Endocrinol, 2025 (external link) |
| SURPASS-PEDS (external link) | Weekly tirzepatide (5 or 10 mg) vs placebo, 30 weeks, 99 children and adolescents with type 2 diabetes | 99 | Eli Lilly | HbA1c fell 2.23 points vs a 0.05 rise on placebo. BMI fell 7.4% and 11.2% vs 0.4%. | Lancet, 2025 (external link) |
| SURPASS-SWITCH (external link) | In adults already on dulaglutide: switching to tirzepatide vs raising the dulaglutide dose, 40 weeks, 282 people | 282 | Eli Lilly | HbA1c fell 1.44 vs 0.67 points; weight fell 10.5 vs 3.6 kg. | Ann Intern Med, 2025 (external link) |
Dulaglutide (AWARD)
AWARD tested weekly dulaglutide, sold as Trulicity, against a wide range of other diabetes drugs.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| AWARD-1 (external link) | Weekly dulaglutide vs twice-daily exenatide vs placebo, 26 weeks, adults on metformin and pioglitazone | 978 | Eli Lilly | HbA1c fell 1.51 and 1.30 points on the two dulaglutide doses vs 0.99 on exenatide and 0.46 on placebo. | Diabetes Care, 2014 (external link) |
| AWARD-2 (external link) | Weekly dulaglutide vs daily insulin glargine, 52 weeks, adults on metformin and a sulfonylurea | 810 | Eli Lilly | HbA1c fell 1.08 points on dulaglutide 1.5 mg vs 0.63 on insulin. Nausea in 15.4% vs 1.5%. | Diabetes Care, 2015 (external link) |
| AWARD-3 (external link) | Weekly dulaglutide vs metformin as the first diabetes drug, 26 weeks | 807 | Eli Lilly | HbA1c fell 0.78 and 0.71 points on dulaglutide vs 0.56 on metformin. | Diabetes Care, 2014 (external link) |
| AWARD-4 (external link) | Weekly dulaglutide vs bedtime insulin glargine, both with mealtime insulin, 52 weeks, open-label | 884 | Eli Lilly | At 26 weeks HbA1c fell 1.64 and 1.59 points on dulaglutide vs 1.41 on glargine. | Lancet, 2015 (external link) |
| AWARD-5 (external link) | Weekly dulaglutide vs sitagliptin, 52 weeks, adults on metformin | 1,202 | Eli Lilly | HbA1c fell 1.10 and 0.87 points on dulaglutide vs 0.39 on sitagliptin. Weight fell 3.03 and 2.60 kg vs 1.53 kg. | Diabetes Care, 2014 (external link) |
| AWARD-6 (external link) | Weekly dulaglutide 1.5 mg vs daily liraglutide 1.8 mg, 26 weeks, adults on metformin | 599 | Eli Lilly | HbA1c fell 1.42 vs 1.36 points. Judged as good as liraglutide, with similar side effects. | Lancet, 2014 (external link) |
| AWARD-7 (external link) | Weekly dulaglutide vs insulin glargine, 52 weeks, 577 adults with type 2 diabetes and moderate to severe kidney disease | 577 | Eli Lilly | HbA1c fell 1.2 and 1.1 points on dulaglutide vs 1.1 on insulin at 26 weeks. | Lancet Diabetes Endocrinol, 2018 (external link) |
| AWARD-8 (external link) | Weekly dulaglutide 1.5 mg vs placebo added to a sulfonylurea, 24 weeks, 300 adults | 300 | Eli Lilly | HbA1c fell 1.3 points more than placebo. 55.3% vs 18.9% reached an HbA1c below 7%. | Diabetes Obes Metab, 2016 (external link) |
| AWARD-9 (external link) | Weekly dulaglutide 1.5 mg vs placebo added to insulin glargine, 28 weeks, 300 adults | 300 | Eli Lilly | HbA1c fell 1.44 vs 0.67 points. Nausea in 12.0% on dulaglutide. | Diabetes Obes Metab, 2017 (external link) |
| AWARD-10 (external link) | Weekly dulaglutide vs placebo added to an SGLT2 inhibitor, 24 weeks | 424 | Eli Lilly | HbA1c fell 1.34 and 1.21 points vs 0.54 on placebo. | Lancet Diabetes Endocrinol, 2018 (external link) |
| AWARD-11 (external link) | Higher weekly dulaglutide doses (3.0 and 4.5 mg) vs the standard 1.5 mg, 52 weeks, 1,842 adults | 1,842 | Eli Lilly | At 36 weeks HbA1c fell 1.77 points on 4.5 mg vs 1.54 on 1.5 mg; weight fell 4.6 vs 3.0 kg. | Diabetes Care, 2021 (external link) |
| AWARD-CHN1 (external link) | Weekly dulaglutide vs glimepiride as the only diabetes drug, 26 weeks, Chinese adults | 737 | Eli Lilly | HbA1c fell 0.53 points more than glimepiride on the 1.5 mg dose. 71.7% vs 57.5% reached an HbA1c below 7%. | J Diabetes Investig, 2020 (external link) |
| AWARD-CHN2 (external link) | Weekly dulaglutide vs daily insulin glargine, 52 weeks, open-label, mainly Asian adults | 774 | Eli Lilly | At 26 weeks HbA1c fell 1.73 and 1.33 points on dulaglutide vs 1.16 on insulin. | Diabetes Obes Metab, 2019 (external link) |
| AWARD-PEDS (external link) | Weekly dulaglutide vs placebo, 26 weeks, 154 young people aged 10 to 17 with type 2 diabetes | 154 | Eli Lilly | HbA1c fell 0.6 and 0.9 points on dulaglutide vs a 0.6 rise on placebo. No effect on BMI. | N Engl J Med, 2022 (external link) |
Liraglutide for type 2 diabetes (LEAD and others)
LEAD was the programme behind daily liraglutide, sold as Victoza, approved in 2010. GRADE is included here because it is rare: a large, publicly funded trial that compared liraglutide directly with three other common diabetes drugs.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| BEGIN (external link) | Adding daily liraglutide vs adding one daily mealtime insulin dose, for people whose diabetes was not controlled on insulin degludec, 26 weeks | 413 | Novo Nordisk | HbA1c fell 0.74 vs 0.39 points. Weight fell 2.8 kg on liraglutide vs a 0.9 kg gain on mealtime insulin. | Diabetes Obes Metab, 2014 (external link) |
| Ellipse (external link) | Daily liraglutide vs placebo, 26 weeks, 135 young people aged 10 to 16 with type 2 diabetes | 135 | Novo Nordisk | HbA1c fell 0.64 points vs a 0.42 rise on placebo, with more stomach and bowel side effects. | N Engl J Med, 2019 (external link) |
| GRADE (external link) | Publicly funded comparison of four drugs added to metformin (liraglutide, insulin glargine, glimepiride, sitagliptin) in 5,047 people, about five years | 7,850 | GRADE Study Group (not a drug company); with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Heart, Lung, and Blood Institute (NHLBI) | Liraglutide and insulin glargine kept HbA1c below 7% longest (about 26 failures per 100 person-years vs 30.4 on glimepiride and 38.1 on sitagliptin). | N Engl J Med, 2022 (external link) |
| LEAD-1 (external link) | Daily liraglutide vs rosiglitazone vs placebo, each added to glimepiride, 26 weeks, 1,041 adults | 1,041 | Novo Nordisk | HbA1c fell 1.1 points on liraglutide vs 0.4 on rosiglitazone and a 0.2 rise on placebo. | Diabet Med, 2009 (external link) |
| LEAD-2 (external link) | Daily liraglutide vs glimepiride vs placebo, each added to metformin, 26 weeks, 1,091 adults | 1,091 | Novo Nordisk | Blood sugar control was similar to glimepiride. Weight fell 1.8 to 2.8 kg on liraglutide vs a 1.0 kg gain on glimepiride. | Diabetes Care, 2009 (external link) |
| LEAD-3 (external link) (registry: ended early) | Daily liraglutide vs glimepiride as the only diabetes drug, 52 weeks, 746 adults | 746 | Novo Nordisk | HbA1c fell 0.84 and 1.14 points on liraglutide vs 0.51 on glimepiride. | Lancet, 2009 (external link) |
| LEAD-4 (external link) | Daily liraglutide vs placebo added to metformin and a glitazone, 26 weeks, 576 adults | 576 | Novo Nordisk | Weight fell 1.0 and 2.0 kg on liraglutide vs a 0.6 kg gain on placebo; blood sugar control improved. | Diabetes Care, 2009 (external link) |
| LEAD-5 (external link) | Daily liraglutide vs insulin glargine vs placebo, added to metformin and a sulfonylurea, 26 weeks, 581 adults | 584 | Novo Nordisk | HbA1c fell 1.33 points on liraglutide vs 1.09 on insulin glargine. | Diabetologia, 2009 (external link) |
| LEAD-6 (external link) | Daily liraglutide 1.8 mg vs twice-daily exenatide, 26 weeks, open-label, 464 adults | 467 | Novo Nordisk | HbA1c fell 1.12 vs 0.79 points. 54% vs 43% reached an HbA1c below 7%. | Lancet, 2009 (external link) |
| LIRA-PRIME (external link) | Daily liraglutide vs one added oral diabetes drug, up to two years, 1,991 adults treated in primary care | 1,991 | Novo Nordisk | Blood sugar stayed controlled for a median 109 weeks on liraglutide vs 65 weeks. 7.9% vs 4.1% stopped because of side effects. | Diabetes Obes Metab, 2022 (external link) |
Exenatide (DURATION)
Exenatide was the first GLP-1 drug. DURATION tested the once-weekly version, sold as Bydureon, against the original twice-daily injection and other diabetes drugs.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| DURATION-1 (external link) | Weekly exenatide vs twice-daily exenatide, 30 weeks, 295 adults | 303 | AstraZeneca | HbA1c fell 1.9 vs 1.5 points. 77% vs 61% reached an HbA1c of 7% or less. | Lancet, 2008 (external link) |
| DURATION-2 (external link) | Weekly exenatide vs sitagliptin vs pioglitazone, 26 weeks, adults on metformin | 514 | AstraZeneca | HbA1c fell 1.5 points on exenatide vs 0.9 on sitagliptin and 1.2 on pioglitazone. | Lancet, 2010 (external link) |
| DURATION-3 (external link) | Weekly exenatide vs daily insulin glargine, 26 weeks, open-label | 467 | AstraZeneca | HbA1c fell 1.5 vs 1.3 points. 5% vs 1% stopped because of side effects. | Lancet, 2010 (external link) |
| DURATION-4 (external link) | Weekly exenatide vs metformin vs pioglitazone vs sitagliptin, 26 weeks, 820 adults on no diabetes drugs | 820 | AstraZeneca | HbA1c fell 1.53 points on exenatide vs 1.48 on metformin, 1.63 on pioglitazone and 1.15 on sitagliptin. | Diabetes Care, 2012 (external link) |
| DURATION-5 (external link) | Weekly exenatide vs twice-daily exenatide, 24 weeks, 252 adults | 254 | AstraZeneca | HbA1c fell 1.6 vs 0.9 points. Weight fell 2.3 vs 1.4 kg. | J Clin Endocrinol Metab, 2011 (external link) |
| DURATION-6 (external link) | Weekly exenatide vs daily liraglutide 1.8 mg, 26 weeks, open-label, 912 adults | 912 | AstraZeneca | HbA1c fell 1.28 points on exenatide vs 1.48 on liraglutide. Nausea in 9% vs 21%. | Lancet, 2013 (external link) |
| DURATION-7 (external link) | Weekly exenatide vs placebo added to insulin glargine, 28 weeks, 464 adults | 464 | AstraZeneca | HbA1c fell 0.73 points more than placebo. 32.5% vs 7.4% reached an HbA1c below 7%. | Diabetes Obes Metab, 2018 (external link) |
| DURATION-8 (external link) | Weekly exenatide plus dapagliflozin vs either drug alone, 28 weeks, 695 adults on metformin | 695 | AstraZeneca | HbA1c fell 2.0 points on the combination vs 1.6 on exenatide alone and 1.4 on dapagliflozin alone. | Lancet Diabetes Endocrinol, 2016 (external link) |
| DURATION-NEO-1 (external link) | A new weekly exenatide pen (autoinjector suspension) vs twice-daily exenatide, 28 weeks, open-label | 377 | AstraZeneca | HbA1c fell 1.4 vs 1.0 points. | Diabetes Obes Metab, 2018 (external link) |
| DURATION-NEO-2 (external link) | The weekly exenatide pen vs sitagliptin vs placebo, 28 weeks, open-label, adults on metformin | 365 | AstraZeneca | HbA1c fell 1.13 points on exenatide vs 0.75 on sitagliptin and 0.40 on placebo. | Diabetes Obes Metab, 2017 (external link) |
Lixisenatide (GetGoal)
GetGoal tested daily lixisenatide, sold as Adlyxin in the US and Lyxumia in Europe. Its effect on HbA1c was smaller than the weekly drugs above.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| GetGoal-Duo 1 (external link) | Daily lixisenatide vs placebo added to newly started insulin glargine, 24 weeks, 446 adults | 446 | Sanofi | HbA1c fell a further 0.71 vs 0.40 points. 56% vs 39% reached an HbA1c below 7%. | Diabetes Care, 2013 (external link) |
| GetGoal-Duo 2 (external link) | Daily lixisenatide vs mealtime insulin once or three times a day, all added to insulin glargine, 26 weeks, 894 adults | 894 | Sanofi | HbA1c reached 7.2% on lixisenatide vs 7.2% and 7.0% on the two mealtime insulin schedules. | Diabetes Care, 2016 (external link) |
| GetGoal-F1 (external link) | Daily lixisenatide (one-step or two-step dose increase) vs placebo, 24 weeks, adults on metformin | 484 | Sanofi | Blood sugar control improved on both schedules. Weight fell 2.6 to 2.7 kg vs 1.6 kg on placebo. | Diabet Med, 2014 (external link) |
| GetGoal-L (external link) | Daily lixisenatide vs placebo added to basal insulin, 24 weeks, 495 adults | 496 | Sanofi | HbA1c fell 0.4 points more than placebo. 28% vs 12% reached an HbA1c below 7%. | Diabetes Care, 2013 (external link) |
| GetGoal-L-Asia (external link) | Daily lixisenatide vs placebo added to basal insulin, 24 weeks, 311 adults in Asia | 311 | Sanofi | HbA1c fell 0.88 points more than placebo. 9.1% vs 3.2% stopped because of side effects. | Diabetes Obes Metab, 2012 (external link) |
| GetGoal-M (external link) | Daily lixisenatide, morning or evening, vs placebo, 24 weeks, 680 adults on metformin | 680 | Sanofi | HbA1c fell 0.9 points (morning) and 0.8 (evening) vs 0.4 on placebo. | Diabetes Care, 2013 (external link) |
| GetGoal-M-Asia (external link) | Daily lixisenatide vs placebo, 24 weeks, 391 adults in Asia on metformin | 391 | Sanofi | HbA1c fell 0.36 points more than placebo. No difference in weight. | Diabetes Metab Res Rev, 2014 (external link) |
| GetGoal-Mono (external link) | Daily lixisenatide vs placebo as the only diabetes drug, 12 weeks, 361 adults | 361 | Sanofi | HbA1c fell 0.54 and 0.66 points more than placebo on the two dosing schedules. | Diabetes Care, 2012 (external link) |
| GetGoal-O (external link) | Daily lixisenatide vs placebo, 24 weeks, 350 adults aged 70 and over | 350 | Sanofi | HbA1c fell 0.57 points vs a 0.06 rise on placebo. Low blood sugar reported by 17.6% vs 10.3%. | Diabetes Care, 2017 (external link) |
| GetGoal-P (external link) | Daily lixisenatide vs placebo added to pioglitazone, 24 weeks, 484 adults | 484 | Sanofi | HbA1c fell 0.56 points more than placebo. 52.3% vs 26.4% reached an HbA1c below 7%. | Diabetes Obes Metab, 2013 (external link) |
| GetGoal-S (external link) | Daily lixisenatide vs placebo added to a sulfonylurea, 24 weeks, 859 adults | 859 | Sanofi | HbA1c fell 0.85 vs 0.10 points. | J Diabetes Complications, 2014 (external link) |
| GetGoal-X (external link) | Daily lixisenatide vs twice-daily exenatide, 24 weeks, open-label, adults on metformin | 639 | Sanofi | HbA1c fell 0.79 vs 0.96 points, judged as good as exenatide. Nausea in 24.5% vs 35.1%. | Diabetes Care, 2013 (external link) |
Albiglutide (HARMONY)
HARMONY tested weekly albiglutide, sold as Tanzeum. The drug is no longer on the market; our history of GLP-1 medications explains why. Its heart-outcomes trial appears in the heart, kidney and survival section above.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| HARMONY 2 (external link) | Weekly albiglutide 30 or 50 mg vs placebo as the only diabetes drug, 52 weeks, 309 adults | 309 | GSK | HbA1c fell 0.84 and 1.04 points more than placebo. | Diabetologia, 2016 (external link) |
| HARMONY 4 (external link) | Weekly albiglutide vs daily insulin glargine, 52 weeks, open-label, 779 adults on metformin | 779 | GSK | HbA1c fell from 8.28% to 7.62% vs 8.36% to 7.55% on insulin. Judged as good as insulin. | Diabetologia, 2014 (external link) |
| HARMONY 6 (external link) | Weekly albiglutide vs mealtime insulin three times a day, both added to basal insulin, 26 weeks | 586 | GSK | HbA1c fell 0.82 vs 0.66 points. Symptomatic low blood sugar in 15.8% vs 29.9%. | Diabetes Care, 2014 (external link) |
| HARMONY 7 (external link) | Weekly albiglutide vs daily liraglutide, 32 weeks, open-label, 841 adults | 841 | GSK | HbA1c fell 0.78 vs 0.99 points. Albiglutide did not meet the bar for being as good as liraglutide. | Lancet Diabetes Endocrinol, 2014 (external link) |
GLP-1 and insulin in one injection (DUAL, LixiLan, COMBINE)
These trials test fixed combinations of a GLP-1 drug and a long-acting insulin in a single pen: IDegLira (Xultophy), iGlarLixi (Soliqua) and the once-weekly IcoSema. The usual question is whether the combination controls blood sugar better than either part alone, with less weight gain than insulin.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| COMBINE 1 (external link) | Weekly IcoSema (insulin icodec plus semaglutide in one injection) vs weekly insulin icodec alone, 52 weeks, 1,291 adults on basal insulin | 1,291 | Novo Nordisk | HbA1c fell 1.55 vs 0.89 points. | Lancet Diabetes Endocrinol, 2025 (external link) |
| COMBINE 2 (external link) | Weekly IcoSema vs weekly semaglutide 1.0 mg, 52 weeks, 683 adults already on a GLP-1 drug | 683 | Novo Nordisk | HbA1c fell 1.35 vs 0.90 points. | Diabetologia, 2025 (external link) |
| COMBINE 4 (external link) | Weekly IcoSema vs daily insulin glargine, 40 weeks, 485 adults new to insulin with poorly controlled type 2 diabetes | 485 | Novo Nordisk | HbA1c fell 3.32 vs 2.44 points. Weight fell 0.79 kg on IcoSema vs a 3.81 kg gain on insulin. | Lancet Diabetes Endocrinol, 2026 (external link) |
| DUAL I (external link) | Daily IDegLira (insulin degludec plus liraglutide in one injection) vs each drug alone, 26 weeks, open-label, 1,663 adults | 1,663 | Novo Nordisk | HbA1c fell 1.9 points on the combination vs 1.4 on insulin degludec and 1.3 on liraglutide. | Lancet Diabetes Endocrinol, 2014 (external link) |
| DUAL I China (external link) | Daily IDegLira vs each component alone, 26 weeks, 720 Chinese adults | 720 | Novo Nordisk | 77.0% reached an HbA1c below 7% on the combination vs 46.4% on insulin degludec and 48.3% on liraglutide. | J Diabetes, 2022 (external link) |
| DUAL I Japan (external link) | Daily IDegLira vs each component alone, 52 weeks, 819 Japanese adults | 819 | Novo Nordisk | Blood sugar control was better on the combination than on either drug alone. Weight rose 2.9 kg on the combination vs 4.1 kg on insulin, and fell 1.0 kg on liraglutide. | Diabetes Obes Metab, 2019 (external link) |
| DUAL II (external link) | Daily IDegLira vs insulin degludec at the same insulin dose, 26 weeks, double-blind, 413 adults | 413 | Novo Nordisk | HbA1c fell 1.9 vs 0.9 points, isolating what the liraglutide part adds. | Diabetes Care, 2014 (external link) |
| DUAL II Japan (external link) | Daily IDegLira vs insulin degludec, 26 weeks, 210 Japanese adults already on insulin | 210 | Novo Nordisk | Blood sugar control was better on the combination. Weight fell 0.7 kg vs a 0.7 kg gain. | Diabetes Obes Metab, 2019 (external link) |
| DUAL III (external link) | Switching to IDegLira vs staying on a GLP-1 drug alone, 26 weeks, open-label, 438 adults | 438 | Novo Nordisk | HbA1c fell from 7.8% to 6.4% after switching vs 7.7% to 7.4% staying put. Weight rose 2.0 kg vs a 0.8 kg fall. | Diabetes Ther, 2017 (external link) |
| DUAL IV (external link) | Daily IDegLira vs placebo added to a sulfonylurea, 26 weeks, double-blind, 435 adults | 435 | Novo Nordisk | HbA1c fell from 7.9% to 6.4% vs to 7.4% on placebo. Confirmed low blood sugar in 41.7% vs 17.1%. | Diabet Med, 2017 (external link) |
| DUAL IX (external link) | Daily IDegLira vs insulin glargine added to an SGLT2 inhibitor, 26 weeks, open-label, 420 adults | 420 | Novo Nordisk | HbA1c fell 1.9 vs 1.7 points, with 1.92 kg less weight and fewer low blood sugar episodes. | Diabetes Obes Metab, 2019 (external link) |
| DUAL V (external link) | Switching to IDegLira vs raising the insulin glargine dose, 26 weeks, open-label, 557 adults | 557 | Novo Nordisk | HbA1c fell 1.81 vs 1.13 points. Weight fell 1.4 kg vs a 1.8 kg gain, with fewer low blood sugar episodes. | JAMA, 2016 (external link) |
| DUAL VI (external link) | Two ways of adjusting the IDegLira dose (once vs twice a week), 32 weeks, 420 adults | 420 | Novo Nordisk | HbA1c fell from 8.2% to 6.1% and from 8.1% to 6.0%. The simpler once-weekly adjustment worked as well. | Diabetes Obes Metab, 2017 (external link) |
| DUAL VIII (external link) | Daily IDegLira vs insulin glargine as the first injectable, two years, open-label, 1,012 adults | 1,012 | Novo Nordisk | 37% on the combination needed stronger treatment within two years vs 66% on insulin glargine. | Lancet Diabetes Endocrinol, 2019 (external link) |
| LixiLan JP-L (external link) | Daily iGlarLixi (insulin glargine plus lixisenatide in one injection) vs insulin glargine, 26 weeks, 512 Japanese adults on insulin | 513 | Sanofi | HbA1c fell 1.27 vs 0.53 points. 51.8% vs 16.0% reached an HbA1c below 7%. | Diabetes Obes Metab, 2020 (external link) |
| LixiLan JP-O1 (external link) | Daily iGlarLixi vs lixisenatide alone, 52 weeks, open-label, 321 Japanese adults | 321 | Sanofi | At 26 weeks HbA1c fell 1.58 vs 0.51 points. Stomach and bowel side effects in 36.0% vs 50.0%. | Diabetes Care, 2020 (external link) |
| LixiLan JP-O2 (external link) | Daily iGlarLixi vs insulin glargine, 26 weeks, open-label, 521 Japanese adults on oral diabetes drugs | 521 | Sanofi | HbA1c fell 1.40 vs 0.76 points. 71.5% vs 38.5% reached an HbA1c below 7%. | Diabetes Obes Metab, 2020 (external link) |
| LixiLan ONE CAN (external link) | Adjusting the iGlarLixi dose daily vs weekly, 26 weeks, open-label, 265 adults in Canada | 265 | Sanofi | HbA1c fell 1.24 points with daily adjustment vs 0.92 with weekly adjustment. | Diabetes Obes Metab, 2022 (external link) |
| LixiLan-G (external link) | Switching to iGlarLixi vs staying on a GLP-1 drug alone, 26 weeks, open-label, 514 adults | 514 | Sanofi | HbA1c reached 6.7% after switching vs 7.4% staying put. 62% vs 26% reached an HbA1c below 7%. | Diabetes Care, 2019 (external link) |
| LixiLan-L (external link) | Daily iGlarLixi vs insulin glargine, 30 weeks, open-label, 736 adults already on basal insulin | 736 | Sanofi | HbA1c fell 1.1 vs 0.6 points. Weight fell 0.7 kg vs a 0.7 kg gain. | Diabetes Care, 2016 (external link) |
| LixiLan-L-CN (external link) | Daily iGlarLixi vs insulin glargine, 30 weeks, 426 Chinese adults on basal insulin | 426 | Sanofi | HbA1c reached 6.7% vs 7.4%. 63.3% vs 29.9% reached an HbA1c below 7%. | Diabetes Obes Metab, 2022 (external link) |
| LixiLan-O (external link) | Daily iGlarLixi vs insulin glargine vs lixisenatide, 30 weeks, open-label, 1,170 adults on metformin | 1,170 | Sanofi | HbA1c fell 1.6 points on the combination vs 1.3 on insulin and 0.9 on lixisenatide. | Diabetes Care, 2016 (external link) |
| LixiLan-O-AP (external link) | Daily iGlarLixi vs insulin glargine vs lixisenatide, 24 weeks, open-label, 878 adults in Asia-Pacific | 878 | Sanofi | HbA1c fell 1.9 points on the combination vs 1.4 on insulin and 0.9 on lixisenatide. | Diabetes Obes Metab, 2022 (external link) |
| REMIT-IDegLira (external link) | A 16-week intensive programme including IDegLira vs standard care, aiming to put early type 2 diabetes into remission, 159 adults | 159 | Population Health Research Institute (not a drug company); with Novo Nordisk | Remission a year later was not significantly more common (6.3% vs 3.8%). Run by a research institute, with Novo Nordisk as a collaborator. | Diabetes Obes Metab, 2024 (external link) |
Drugs not yet approved in the US
None of the drugs in this section is approved in the United States as of September 20, 2026. Results here come from completed, published trials, several of them mid-stage (phase 2) trials that are smaller and shorter than the ones above. Treat them as early evidence. CagriSema combines semaglutide with cagrilintide, an amylin-type drug; retatrutide, survodutide, mazdutide and pemvidutide act on glucagon as well as GLP-1.
| Trial | What it tested | People | Sponsor | Headline result | Paper |
|---|---|---|---|---|---|
| AMPLITUDE-M (external link) | Weekly efpeglenatide (2, 4 or 6 mg) vs placebo, 30 weeks, 406 adults managing type 2 diabetes with diet and exercise | 406 | Hanmi | HbA1c fell 0.5, 0.8 and 1.0 points more than placebo. | Diabetes Care, 2022 (external link) |
| AMPLITUDE-O (external link) (registry: ended early) | Weekly efpeglenatide vs placebo in 4,076 people with type 2 diabetes and heart or kidney disease, median 1.81 years | 4,076 | Sanofi | Major heart events in 7.0% vs 9.2% (hazard ratio 0.73). Kidney events in 13.0% vs 18.4%. | N Engl J Med, 2021 (external link) |
| Danuglipron phase 2, obesity (external link) | Twice-daily danuglipron pill vs placebo, 26 or 32 weeks, 628 adults with obesity (phase 2) | 628 | Pfizer | Weight fell 5.0 to 12.9 percentage points more than placebo, but only 39.3% completed treatment and about 38% stopped because of side effects. | Diabetes Obes Metab, 2025 (external link) |
| DREAMS-2 (external link) | Weekly mazdutide (4 or 6 mg) vs dulaglutide 1.5 mg, 28 weeks, 731 Chinese adults with type 2 diabetes | 731 | Innovent Biologics | HbA1c fell 0.24 and 0.30 points more than dulaglutide; weight fell 3.78 and 5.76 percentage points more. | Nature, 2026 (external link) |
| Ecnoglutide monotherapy (external link) | Weekly ecnoglutide vs placebo as the only diabetes drug, 24 weeks, 211 Chinese adults | 211 | Sciwind Biosciences | HbA1c fell 1.96 and 2.43 points vs 0.87 on placebo. | Nat Commun, 2026 (external link) |
| Ecnoglutide phase 3, obesity (external link) | Weekly ecnoglutide (1.2, 1.8 or 2.4 mg) vs placebo, 40 weeks, 664 Chinese adults with overweight or obesity | 664 | Sciwind Biosciences | Weight fell 9.1%, 10.9% and 13.2% vs a 0.1% rise on placebo. | Lancet Diabetes Endocrinol, 2025 (external link) |
| Ecnoglutide vs dulaglutide (external link) | Weekly ecnoglutide vs dulaglutide 1.5 mg, 32 weeks, 623 Chinese adults with type 2 diabetes | 623 | Sciwind Biosciences | HbA1c fell 1.91 and 1.89 points on ecnoglutide vs 1.65 on dulaglutide. | Lancet Diabetes Endocrinol, 2025 (external link) |
| GLORY-1 (external link) | Weekly mazdutide (4 or 6 mg) vs placebo, 48 weeks, 610 Chinese adults with overweight or obesity | 610 | Innovent Biologics | At week 32 weight fell 10.09% and 12.55% vs a 0.45% rise on placebo. | N Engl J Med, 2025 (external link) |
| GLORY-2 (external link) (registry: status not updated) | A higher weekly mazdutide dose (9 mg) vs placebo, 60 weeks, 462 Chinese adults with obesity | 462 | Innovent Biologics | Weight fell 16.65% vs 1.50% on placebo. | JAMA, 2026 (external link) |
| IMPACT (external link) | Weekly pemvidutide vs placebo, 24 weeks, 212 people with MASH and liver scarring (phase 2) | 212 | Altimmune | Liver inflammation resolved in 58% and 52% vs 20% on placebo. Scarring did not improve more than on placebo, so one of the two main goals was missed. | Lancet, 2025 (external link) |
| MariTide phase 2 (external link) | Maridebart cafraglutide (MariTide) injected every four or eight weeks vs placebo, 52 weeks, 592 adults (phase 2) | 592 | Amgen | In people with obesity and no diabetes, weight fell 12.3% to 16.2% vs 2.5% on placebo. | N Engl J Med, 2025 (external link) |
| REDEFINE 1 (external link) (registry: follow-up still running) | Weekly cagrilintide plus semaglutide (CagriSema) vs each drug alone vs placebo, 68 weeks, 3,400 adults with obesity | 3,400 | Novo Nordisk | Weight fell 20.4% on the combination vs 3.0% on placebo. | N Engl J Med, 2025 (external link) |
| REDEFINE 2 (external link) | Weekly CagriSema vs placebo, 68 weeks, 1,200 adults with obesity and type 2 diabetes | 1,200 | Novo Nordisk | Weight fell 13.7% vs 3.4%. 73.5% vs 15.9% reached an HbA1c of 6.5% or less. | N Engl J Med, 2025 (external link) |
| REIMAGINE 1 (external link) | Weekly CagriSema at two doses vs placebo, 40 weeks, 189 adults managing type 2 diabetes with diet and exercise | 189 | Novo Nordisk | HbA1c fell 1.8 and 1.5 points vs 0.1 on placebo. Weight fell 13.8% and 11.8% vs 1.4%. | Lancet Diabetes Endocrinol, 2026 (external link) |
| REIMAGINE 2 (external link) | Weekly CagriSema vs semaglutide alone vs cagrilintide alone vs placebo, 68 weeks, 2,734 adults with type 2 diabetes | 2,734 | Novo Nordisk | HbA1c fell 1.91 points on the combination vs 1.75 on semaglutide 2.4 mg alone, a small added benefit. | Lancet Diabetes Endocrinol, 2026 (external link) |
| REIMAGINE 3 (external link) | Weekly CagriSema vs placebo added to basal insulin, 40 weeks, 274 adults with type 2 diabetes | 274 | Novo Nordisk | HbA1c fell 2.33 and 2.10 points on the two doses vs 0.66 on placebo. | Lancet, 2026 (external link) |
| Retatrutide phase 2, obesity (external link) | Weekly retatrutide (1 to 12 mg) vs placebo, 48 weeks, 338 adults with obesity (phase 2) | 338 | Eli Lilly | Weight fell 8.7% to 24.2% depending on dose vs 2.1% on placebo. | N Engl J Med, 2023 (external link) |
| Retatrutide phase 2, type 2 diabetes (external link) | Weekly retatrutide vs placebo vs dulaglutide, 36 weeks, 281 adults with type 2 diabetes (phase 2) | 281 | Eli Lilly | At 24 weeks HbA1c fell up to 2.02 points vs 0.01 on placebo. At 36 weeks weight fell up to 16.94% vs 3.00% on placebo and 2.02% on dulaglutide. | Lancet, 2023 (external link) |
| Retatrutide phase 3, type 2 diabetes (external link) | Weekly retatrutide (4, 9 or 12 mg) vs placebo, 40 weeks, 537 adults managing type 2 diabetes with diet and exercise | 537 | Eli Lilly | HbA1c fell 1.69, 1.86 and 1.94 points vs 0.81 on placebo. | Lancet, 2026 (external link) |
| Survodutide phase 2, MASH (external link) | Weekly survodutide vs placebo, 48 weeks, 295 people with MASH and liver scarring (phase 2) | 295 | Boehringer Ingelheim | MASH improved without worse scarring in 47%, 62% and 43% across the doses vs 14% on placebo. Nausea in 66% vs 23%. | N Engl J Med, 2024 (external link) |
| Survodutide phase 2, obesity (external link) | Weekly survodutide (0.6 to 4.8 mg) vs placebo, 46 weeks, 387 adults with overweight or obesity (phase 2) | 387 | Boehringer Ingelheim | Weight fell 6.2% to 14.9% depending on dose vs 2.8% on placebo. | Lancet Diabetes Endocrinol, 2024 (external link) |
| SYNCHRONIZE-1 (external link) | Weekly survodutide (up to 3.6 or 6.0 mg) vs placebo, 76 weeks, 726 adults with obesity and no diabetes | 726 | Boehringer Ingelheim | Weight fell 12.2% and 13.0% vs 5.4% on placebo. | N Engl J Med, 2026 (external link) |
| Visepegenatide (PB-119) phase 3 (external link) | Weekly visepegenatide vs placebo, 24 weeks, 273 Chinese adults with type 2 diabetes (drug not approved in the US) | 273 | PegBio | HbA1c fell 1.36 vs 0.63 points. | Lancet Reg Health West Pac, 2024 (external link) |
Who paid for these trials
Of the 205 trials on this page, 199 were sponsored by drug companies and 6 by public bodies, universities or research networks.
The largest sponsors were Novo Nordisk (93 trials), Eli Lilly (52 trials), Sanofi (23 trials), AstraZeneca (11 trials) and GSK (5 trials), followed by Boehringer Ingelheim, Innovent Biologics and Sciwind Biosciences (3 trials each).
The trials not sponsored by a drug company were: Exenatide-PD3 (University College, London), FIGHT (Duke University), GRADE (GRADE Study Group), LEAN (University of Birmingham), REMIT-IDegLira (Population Health Research Institute), RISE Adult (RISE Study Group). Some of these still received the study drug or part of their funding from a manufacturer.
This pattern is normal for prescription drugs, and it is worth keeping in mind. A company decides which questions get a trial. Questions that could shrink sales, such as how low a dose can go or how long someone can safely pause, get studied late or not at all. The few trials on those questions are covered in our guides on stopping a GLP-1 and tapering vs. staying on a maintenance dose.
Finished trials with no published results yet
The registry lists these trials as completed, but we could not find a peer-reviewed results paper linked to them as of September 20, 2026. Some have only a design paper so far. They are listed so the page is honest about what it leaves out. We report no results for them.
| Trial | People | Sponsor | Finished |
|---|---|---|---|
| ACHIEVE-4 (external link) | 2,749 | Eli Lilly | 2026-03-16 |
| ATTAIN-J (external link) | 238 | Eli Lilly | 2025-06-19 |
| ATTAIN-OSA (external link) | 712 | Eli Lilly | 2026-07-30 |
| AWARD-CHN3 (external link) | 291 | Eli Lilly | 2022-04-28 |
| AWARD-JPN (external link) | 591 | Eli Lilly | 2023-04-26 |
| DUAL II China (external link) | 453 | Novo Nordisk | 2019-04-04 |
| EVOLVE-2 (external link) | 206 | Verdiva Bio Dev Limited | 2026-07-23 |
| OASIS 3 (external link) | 200 | Novo Nordisk | 2025-01-16 |
| PIONEER TEENS (external link) | 132 | Novo Nordisk | 2026-02-03 |
| REDEFINE 6 (external link) | 300 | Novo Nordisk | 2025-02-22 |
| REIMAGINE 5 (external link) | 1,023 | Novo Nordisk | 2026-07-09 |
| REMIT-iGL (external link) | 161 | Population Health Research Institute | 2020-09-30 |
| REMODEL (external link) | 106 | Novo Nordisk | 2024-11-21 |
| SYNCHRONIZE-2 (external link) | 755 | Boehringer Ingelheim | 2026-04-01 |
| SYNCHRONIZEJP (external link) | 274 | Boehringer Ingelheim | 2025-12-03 |
| TRIUMPH-1 (external link) | 2,335 | Eli Lilly | 2026-04-30 |
| TRIUMPH-2 (external link) | 1,152 | Eli Lilly | 2026-06-16 |
| TRIUMPH-3 (external link) | 1,946 | Eli Lilly | 2026-05-14 |
| TRIUMPH-4 (external link) | 445 | Eli Lilly | 2025-11-14 |
How this page was built
We searched ClinicalTrials.gov for completed phase 3 trials of every GLP-1 drug (and phase 2 or 3 trials of drugs still in development) that carry a trial name. We kept company-sponsored trials with at least 90 participants and other trials with at least 150, which leaves out small single-hospital studies. For each trial we found the main results paper on PubMed, mostly through the registration number the paper reports, and added well-known trials that the registry search missed.
Sponsor, enrollment and completion status come from the registry. Results come from each paper's published summary; where we could not read the full paper, the summary is all we had. Every paper link was checked against the publisher's record, and every number in the results column was checked against the paper's summary.
The page will date. Trials finish, results get published, and drugs in the last section get approved or abandoned. Last verified: September 20, 2026. If you spot an error or a missing trial, use the report link on this page.
Study findings are attributed to their authors and were located via PubMed; trial records are from ClinicalTrials.gov. This page is general education and peer information, not medical advice. A trial result is not a prediction for one person; decisions about your treatment belong with the prescriber who knows your history.